Iovance Biotherapeutics, Inc. (IOVA)

Panagora Asset Management Inc. Has $2.82 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Panagora Asset Management Inc. boosted its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 346,190 shares of the biotechnology company’s stock after acquiring an additional 12,216 shares during the period. Panagora Asset Management Inc. owned 0.14% of Iovance Biotherapeutics worth $2,815,000 at the end of the most recent reporting period. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC increased its position in shares of Iovance Biotherapeutics by 1,227.8% in the fourth quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 4,678 shares during the period. Annandale Capital LLC bought a new position in Iovance Biotherapeutics in the 3rd quarter valued at about $32,000. Nisa Investment Advisors LLC raised its position in shares of Iovance Biotherapeutics by 284.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 5,577 shares in the last quarter. Clear Street Markets LLC bought a new stake in shares of Iovance Biotherapeutics during the 3rd quarter worth approximately $35,000. Finally, Signaturefd LLC boosted its position in shares of Iovance Biotherapeutics by 256.6% during the 4th quarter. Signaturefd LLC now owns 8,723 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 6,277 shares in the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds. Iovance Biotherapeutics Price Performance Shares of IOVA stock opened at $10.24 on Monday. The stock has a 50-day moving average of $13.00 and a 200-day moving average of $10.13. Iovance Biotherapeutics, Inc. has a 1-year low of $3.21 and a 1-year high of $18.33. Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.03. Iovance Biotherapeutics had a negative net margin of 23,615.70% and a negative return on equity of 71.45%. The firm had revenue of $0.72 million for the quarter, compared to the consensus estimate of $1.99 million. During the same quarter in the previous year, the company earned ($0.50) EPS. The company’s revenue for the quarter was up 71400.0% on a year-over-year basis. Research analysts expect that Iovance Biotherapeutics, Inc. will post -1.37 earnings per share for the current year. Analyst Upgrades and Downgrades A number of equities research analysts have weighed in on the company. StockNews.com raised Iovance Biotherapeutics to a “sell” rating in a report on Friday, February 2nd. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, May 10th. Chardan Capital boosted their target price on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their price target on Iovance Biotherapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, Wells Fargo & Company boosted their price objective on Iovance Biotherapeutics from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.64. View Our Latest Report on IOVA Insiders Place Their Bets In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $9.15 per share, for a total transaction of $2,287,500.00. Following the transaction, the director now directly owns 320,150 shares in the company, valued at $2,929,372.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.40% of the company’s stock. About Iovance Biotherapeutics (Free Report) Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.